[Long-term outcomes of 125I brachytherapy combined with maximal androgen blockade for metastatic prostate cancer].

MLA

Luo, Peng-Wei, et al. “[Long-Term Outcomes of 125I Brachytherapy Combined with Maximal Androgen Blockade for Metastatic Prostate Cancer].” Zhonghua Nan Ke Xue = National Journal of Andrology, vol. 25, no. 1, Jan. 2019, pp. 29–34. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=cmedm&AN=32212502&authtype=sso&custid=ns315887.

APA

Luo, P.-W., Wang, L., Cao, W.-F., Li, S.-D., Huang, X.-K., Liu, J.-W., Zhao, Y.-G., Zhou, T.-T., Yang, S.-W., & Qin, S.-Y. (2019). [Long-term outcomes of 125I brachytherapy combined with maximal androgen blockade for metastatic prostate cancer]. Zhonghua Nan Ke Xue = National Journal of Andrology, 25(1), 29–34.

Chicago

Luo, Peng-Wei, Liang Wang, Wen-Feng Cao, Sha-Dan Li, Xiao-Ke Huang, Ji-Wen Liu, You-Guang Zhao, Ting-Ting Zhou, Shi-Wei Yang, and Shi-Yuan Qin. 2019. “[Long-Term Outcomes of 125I Brachytherapy Combined with Maximal Androgen Blockade for Metastatic Prostate Cancer].” Zhonghua Nan Ke Xue = National Journal of Andrology 25 (1): 29–34. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=cmedm&AN=32212502&authtype=sso&custid=ns315887.